Back to Search Start Over

A RAS-CaMKKβ-AMPKα2 pathway promotes senescence by licensing post-translational activation of C/EBPβ through a novel 3'UTR mechanism

Authors :
Kevin P. Claffey
Peter F. Johnson
Mesfin Gonit
Myriam Gorospe
Atharva Bhat
Jacqueline Salotti
Jiji Chen
Sandip K. Basu
Benoit Viollet
Mouse Cancer Genetics Program [Frederick, MD, USA] (Center for Cancer Research)
National Cancer Institute [Bethesda] (NCI-NIH)
National Institutes of Health [Bethesda] (NIH)-National Institutes of Health [Bethesda] (NIH)-Center for Cancer Research [Frederick, MD, USA]
Lentigen Tech, Inc. [Gaithersburg, MD, USA]
Cancer and Inflammation Program [Frederick, MD, USA] (Leidos Biomedical Research Inc.)
Frederick National Laboratory for Cancer Research (FNLCR)-NCI-Frederick
Advanced Imaging and Microscopy Resource [Bethesda, MD, USA]
National Institutes of Health [Bethesda] (NIH)
Laboratory of Genetics [Baltimore, MD, USA] (National Institute on Aging-Intramural Research Program)
[Institut Cochin] Département Endocrinologie, métabolisme, diabète (EMD) (EMD)
Institut Cochin (IC UM3 (UMR 8104 / U1016))
Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Department of Cell Biology [Farmington, CT, USA]
University of Connecticut (UCONN)
This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.
Viollet, Benoit
Source :
Oncogene, Oncogene, Nature Publishing Group, 2018, 37 (26), pp.3528-3548. ⟨10.1038/s41388-018-0190-7⟩, Oncogene, 2018, 37 (26), pp.3528-3548. ⟨10.1038/s41388-018-0190-7⟩
Publication Year :
2017

Abstract

International audience; Oncogene-induced senescence (OIS) is an intrinsic tumor suppression mechanism that requires the p53 and RB pathways and post-translational activation of C/EBPβ through the RAS-ERK cascade. We previously reported that in transformed/proliferating cells, C/EBPβ activation is inhibited by G/U-rich elements (GREs) in its 3'UTR. This mechanism, termed "3'UTR regulation of protein activity" (UPA), maintains C/EBPβ in a low-activity state in tumor cells and thus facilitates senescence bypass. Here we show that C/EBPβ UPA is overridden by AMPK signaling. AMPK activators decrease cytoplasmic levels of the GRE binding protein HuR, which is a key UPA component. Reduced cytoplasmic HuR disrupts 3'UTR-mediated trafficking of Cebpb transcripts to the peripheral cytoplasm-a fundamental feature of UPA-thereby stimulating C/EBPβ activation and growth arrest. In primary cells, oncogenic RAS triggers a Ca++-CaMKKβ-AMPKα2-HuR pathway, independent of AMPKα1, that is essential for C/EBPβ activation and OIS. This axis is disrupted in cancer cells through down-regulation of AMPKα2 and CaMKKβ. Thus, CaMKKβ-AMPKα2 signaling constitutes a key tumor suppressor pathway that activates a novel UPA-cancelling mechanism to unmask the cytostatic and pro-senescence functions of C/EBPβ.

Details

ISSN :
14765594 and 09509232
Volume :
37
Issue :
26
Database :
OpenAIRE
Journal :
Oncogene
Accession number :
edsair.doi.dedup.....89f96479720ffa7791b98f5a6d122dc7
Full Text :
https://doi.org/10.1038/s41388-018-0190-7⟩